



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

# PRODUCT INFORMATION




## MT-802

Item No. 36581

**CAS Registry No.:** 2231744-29-7  
**Formal Name:** 2-[2-[2-[4-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]ethoxy]ethoxy]-N-[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl]-acetamide

**MF:** C<sub>41</sub>H<sub>41</sub>N<sub>9</sub>O<sub>8</sub>  
**FW:** 787.8  
**Purity:** ≥95%  
**Supplied as:** A solid  
**Storage:** -20°C  
**Stability:** ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

### Laboratory Procedures

MT-802 is supplied as a solid. A stock solution may be made by dissolving the MT-802 in the solvent of choice, which should be purged with an inert gas. MT-802 is soluble in DMSO and slightly soluble in chloroform and methanol.

### Description

MT-802 is a proteolysis-targeting chimera (PROTAC) composed of the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (Item No. 16274) linked to the cereblon inhibitor pomalidomide (Item No. 19877).<sup>1</sup> It induces degradation of BTK in NAMALWA cells when used at concentrations ranging from 10 to 250 nM. MT-802 (1 μM) induces BTK degradation in primary X-linked agammaglobulinemia (XLA) cells expressing wild-type BTK or the ibrutinib-resistant mutant BTK<sup>C481S</sup>. It also induces BTK degradation in patient-derived chronic lymphocytic leukemia (CLL) cells.

### Reference

1. Buhimschi, A.D., Armstrong, H.A., Toure, M., *et al.* Targeting the C481S ibrutinib-resistance mutation in Bruton's tyrosine kinase using PROTAC-mediated degradation. *Biochemistry* **57(26)**, 3564-3575 (2018).

#### WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

#### SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

#### WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/19/2024

#### CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD  
ANN ARBOR, MI 48108 · USA

**PHONE:** [800] 364-9897  
[734] 971-3335

**FAX:** [734] 971-3640

CUSTSERV@CAYMANCHEM.COM  
WWW.CAYMANCHEM.COM